Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (RAVE)

This study has been completed.
Sponsor:
Collaborators:
Immune Tolerance Network (ITN)
Genentech, Inc.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00104299
First received: February 24, 2005
Last updated: April 14, 2016
Last verified: April 2016
Results First Received: February 2, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Vasculitis
Wegener's Granulomatosis
Microscopic Polyangiitis
Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group)
Drug: Cyclophosphamide plus rituximab placebo (control group)
Drug: Azathioprine
Drug: Methylprednisolone (or other glucocorticoid)
Drug: Prednisone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Eight centers in the United States and one center in the Netherlands (Groningen) enrolled 197 Antineutrophil cytoplasmic antibodies (ANCA)-positive patients with either Wegener’s granulomatosis or microscopic polyangiitis between December 30, 2004 and June 30, 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
At a screening visit, participants underwent procedures to establish inclusion/exclusion criteria and then sign the informed consent form.

Reporting Groups
  Description
Rituximab Participants received intravenous rituximab (Rituxan, Genentech) (at a dose of 375 mg per square meter of body-surface area once weekly for 4 weeks) plus daily placebo−cyclophosphamide. Refer to section titled “Detailed Description” for additional treatment information.
Control Group Participants received placebo−rituximab infusions plus daily cyclophosphamide (2 mg per kilogram of body weight, adjusted for renal insufficiency). Refer to section titled “Detailed Description” for additional treatment information.

Participant Flow:   Overall Study
    Rituximab   Control Group
STARTED   99   98 
COMPLETED   90 [1]   88 [1] 
NOT COMPLETED   9   10 
Adverse Event                3                1 
Death                2                2 
Withdrawal by Subject                2                6 
Physician Decision                1                1 
To have renal transplant                1                0 
[1] Number of participants who completed 18 months post-randomization



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rituximab Participants received intravenous rituximab (Rituxan, Genentech) (at a dose of 375 mg per square meter of body-surface area once weekly for 4 weeks) plus daily placebo−cyclophosphamide. Refer to section titled “Detailed Description” for additional treatment information.
Control Group Participants received placebo−rituximab infusions plus daily cyclophosphamide (2 mg per kilogram of body weight, adjusted for renal insufficiency). Refer to section titled “Detailed Description” for additional treatment information.
Total Total of all reporting groups

Baseline Measures
   Rituximab   Control Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 99   98   197 
Age 
[Units: Participants]
     
<=18 years   3   3   6 
Between 18 and 65 years   60   76   136 
>=65 years   36   19   55 
Age 
[Units: Years]
Mean (Standard Deviation)
 54.0  (16.8)   51.5  (14.1)   52.8  (15.5) 
Gender 
[Units: Participants]
     
Female   52   45   97 
Male   47   53   100 
Region of Enrollment 
[Units: Participants]
     
United States   91   90   181 
Netherlands   8   8   16 
BVAS/WG [1] 
[Units: Score units]
Mean (Standard Deviation)
 8.1  (2.8)   8.0  (3.4)   8.0  (3.1) 
[1] The Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (WG) is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease. In this study, the primary end point was a BVAS/WG score of 0 and successful completion of the prednisone taper at 6 months.
VDI [1] 
[Units: Score units]
Mean (Standard Deviation)
 1.4  (1.8)   1.0  (1.4)   1.2  (1.7) 
[1] Vasculitis Damage Index. The VDI is a validated measure for damage assessment in vasculitis. The index comprises 64 items of damage (divided into 11 organ based systems) representative of damage incurred to patients with systemic vasculitis. Scores for this index range from 0 to 64, with higher scores indicating more severe damage.


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Disease Remission   [ Time Frame: 6 months post-randomization ]

2.  Secondary:   Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy   [ Time Frame: Through common close-out (defined as 18 months after the last participant is enrolled in the trial) ]

3.  Secondary:   Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization   [ Time Frame: 6 months post-randomization ]

4.  Secondary:   The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups   [ Time Frame: 18 months post-randomization ]

5.  Secondary:   The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups   [ Time Frame: 18 months post-randomization ]

6.  Secondary:   Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups   [ Time Frame: 18 months post-randomization ]

7.  Secondary:   Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups   [ Time Frame: 18 months post-randomization ]

8.  Post-Hoc:   Number of Subjects Experiencing Serious Adverse Events   [ Time Frame: Randomization to censor at Crossover, Open-label or Best Medical Judgment (up to 18 months post-randomization) ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame From randomization through common close out (defined as 18 months after the last participant is enrolled in the trial)
Additional Description Adverse events reported include both disease and non-disease related events by originally assigned treatment. No participants are censored from these results. NCI-CTCAE version 3.0 (published June 10, 2003) was used to grade severity.

Reporting Groups
  Description
Rituximab Participants received intravenous rituximab (Rituxan, Genentech) (at a dose of 375 mg per square meter of body-surface area once weekly for 4 weeks) plus daily placebo-cyclophosphamide. Refer to section titled "Detailed Description" for additional treatment information.
Control Group Participants received placebo-rituximab infusions plus daily cyclophosphamide (2 mg per kilogram of body weight, adjusted for renal insufficiency). Refer to section titled "Detailed Description" for additional treatment information.

Serious Adverse Events
    Rituximab   Control Group
Total, Serious Adverse Events     
# participants affected / at risk   60/99 (60.61%)   47/98 (47.96%) 
Blood and lymphatic system disorders     
Anaemia † 1     
# participants affected / at risk   3/99 (3.03%)   4/98 (4.08%) 
# events   3   6 
Autoimmune thrombocytopenia † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Febrile neutropenia † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Leukopenia † 1     
# participants affected / at risk   3/99 (3.03%)   0/98 (0.00%) 
# events   5   0 
Pancytopenia † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Cardiac disorders     
Atrial fibrillation † 1     
# participants affected / at risk   2/99 (2.02%)   0/98 (0.00%) 
# events   2   0 
Atrial tachycardia † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Myocardial infarction † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Supraventricular tachycardia † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Ear and labyrinth disorders     
Sudden hearing loss † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Eye disorders     
Keratitis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Ulcerative keratitis † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Gastrointestinal disorders     
Colitis ischaemic † 1     
# participants affected / at risk   2/99 (2.02%)   0/98 (0.00%) 
# events   2   0 
Diarrhoea † 1     
# participants affected / at risk   2/99 (2.02%)   0/98 (0.00%) 
# events   2   0 
Gastritis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Impaired gastric emptying † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pancreatitis acute † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Upper gastrointestinal haemorrhage † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
General disorders     
Adverse drug reaction † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Asthenia † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Chest pain † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Chills † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Multi-organ failure † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pyrexia † 1     
# participants affected / at risk   2/99 (2.02%)   0/98 (0.00%) 
# events   2   0 
Hepatobiliary disorders     
Cholelithiasis † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Immune system disorders     
Anti-neutrophil cytoplasmic antibody positive vasculitis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Drug hypersensitivity † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Hypersensitivity † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Infections and infestations     
Abdominal abscess † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Abscess limb † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Acute sinusitis † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Bronchitis † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Cellulitis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Cellulitis orbital † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Cellulitis staphylococcal † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Central line infection † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Clostridial infection † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   2   0 
Clostridium difficile colitis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Escherichia infection † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Gastroenteritis viral † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Infective exacerbation of chronic obstructive airways disease † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Influenza † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Lobar pneumonia † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Osteomyelitis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Periorbital cellulitis † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   2 
Pneumocystis jiroveci pneumonia † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Pneumonia † 1     
# participants affected / at risk   8/99 (8.08%)   10/98 (10.20%) 
# events   10   11 
Pneumonia bacterial † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Post streptococcal glomerulonephritis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Respiratory tract infection † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Sepsis † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Septic shock † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Skin infection † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Upper respiratory tract infection † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Urinary tract infection † 1     
# participants affected / at risk   2/99 (2.02%)   1/98 (1.02%) 
# events   2   1 
Viral upper respiratory tract infection † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Injury, poisoning and procedural complications     
Accidental overdose † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Clavicle fracture † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Fall † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pelvic fracture † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Subdural haematoma † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Investigations     
Blood creatinine increased † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
C-reactive protein increased † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Haemoglobin decreased † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Metabolism and nutrition disorders     
Dehydration † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Gout † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Hypercalcaemia † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   2 
Hypovolaemia † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Type 2 diabetes mellitus † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Musculoskeletal and connective tissue disorders     
Bone disorder † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Intervertebral disc protrusion † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Osteoarthritis † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   2   1 
Osteonecrosis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Spinal column stenosis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Bladder transitional cell carcinoma † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Colon cancer † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Colon cancer metastatic † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Lung neoplasm malignant † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Prostate cancer † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Squamous cell carcinoma of skin † 1     
# participants affected / at risk   0/99 (0.00%)   2/98 (2.04%) 
# events   0   6 
Thyroid cancer † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Uterine cancer † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Nervous system disorders     
Cerebrovascular accident † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Haemorrhagic stroke † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Somnolence † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Syncope † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pregnancy, puerperium and perinatal conditions     
Abortion spontaneous † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pregnancy † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Psychiatric disorders     
Depression † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Suicidal ideation † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Suicide attempt † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Renal and urinary disorders     
Acute prerenal failure † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Bladder disorder † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Nephrolithiasis † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Renal failure † 1     
# participants affected / at risk   4/99 (4.04%)   2/98 (2.04%) 
# events   4   2 
Renal failure acute † 1     
# participants affected / at risk   2/99 (2.02%)   3/98 (3.06%) 
# events   2   3 
Renal failure chronic † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Urinary incontinence † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Reproductive system and breast disorders     
Endometriosis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Respiratory, thoracic and mediastinal disorders     
Acute respiratory distress syndrome † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Chronic obstructive pulmonary disease † 1     
# participants affected / at risk   0/99 (0.00%)   1/98 (1.02%) 
# events   0   1 
Dyspnoea † 1     
# participants affected / at risk   2/99 (2.02%)   0/98 (0.00%) 
# events   2   0 
Interstitial lung disease † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Laryngeal stenosis † 1     
# participants affected / at risk   2/99 (2.02%)   2/98 (2.04%) 
# events   2   3 
Lung infiltration † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Pulmonary alveolar haemorrhage † 1     
# participants affected / at risk   2/99 (2.02%)   2/98 (2.04%) 
# events   2   2 
Pulmonary embolism † 1     
# participants affected / at risk   3/99 (3.03%)   2/98 (2.04%) 
# events   3   2 
Pulmonary haemorrhage † 1     
# participants affected / at risk   1/99 (1.01%)   1/98 (1.02%) 
# events   1   1 
Wegener's granulomatosis † 1     
# participants affected / at risk   8/99 (8.08%)   4/98 (4.08%) 
# events   9   5 
Vascular disorders     
Aortic dissection † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Deep vein thrombosis † 1     
# participants affected / at risk   1/99 (1.01%)   8/98 (8.16%) 
# events   1   8 
Peripheral arterial occlusive disease † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Thrombosis † 1     
# participants affected / at risk   1/99 (1.01%)   0/98 (0.00%) 
# events   1   0 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 11.1




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information